Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11–13 Weeks?

Publisher： Karger

E-ISSN： 1421-9964|30|1|53-59

ISSN： 1015-3837

Source： Fetal Diagnosis and Therapy, Vol.30, Iss.1, 2011-03, pp. : 53-59

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Screening for Trisomy 21 with Maternal Age, Fetal Nuchal Translucency and Maternal Serum Biochemistry at 11–14 Weeks: A Regional Experience from Germany

By  

Fetal Diagnosis and Therapy, Vol. 21, Iss. 3, 2006-04 ,pp. : 264-268

Karger

Access to resources Recommend Favorite

Maternal Serum Adiponectin at 11–13 Weeks of Gestation in Preeclampsia

By  

Fetal Diagnosis and Therapy, Vol. 29, Iss. 3, 2011-01 ,pp. : 208-215

Karger

Access to resources Recommend Favorite

Single-Step Maternal Serum Screening for Trisomy 21 in the Era of Combined or Integrated Screening

By  

Gynecologic and Obstetric Investigation, Vol. 58, Iss. 4, 2004-11 ,pp. : 221-224

Karger

Access to resources Recommend Favorite

Dilated Fourth Ventricle in Fetuses with Trisomy 18, Trisomy 13 and Triploidy at 11–13 Weeks’ Gestation

By  

Fetal Diagnosis and Therapy, Vol. 32, Iss. 3, 2012-07 ,pp. : 186-189

Karger

Access to resources Recommend Favorite

Cephalic Index Is Not a Useful Sonographic Marker for Trisomy 21 and Trisomy 18

By  

Fetal Diagnosis and Therapy, Vol. 19, Iss. 6, 2004-11 ,pp. : 491-495

Karger

Access to resources Recommend Favorite